Charles River Labs Files 8-K

TL;DR

CRL filed an 8-K updating corporate info - nothing major.

AI Summary

Charles River Laboratories International, Inc. filed an 8-K on January 14, 2025, reporting under Regulation FD. The filing details the company's principal executive offices located at 251 Ballardvale Street, Wilmington, Massachusetts, 01887, and its telephone number, 781-222-6000. The company is incorporated in Delaware and its fiscal year ends on December 28.

Why It Matters

This filing serves as an official update on the company's corporate information, including its principal executive offices and contact details, which are essential for investors and regulatory bodies.

Risk Assessment

Risk Level: low — The filing is a routine corporate update and does not contain any material financial or operational information that would indicate a change in risk.

Key Players & Entities

• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (company) — Filer
• 251 Ballardvale Street, Wilmington, Massachusetts, 01887 (location) — Principal Executive Offices
• January 14, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common stock, $0.01 par value CRL New York Stock Exchange

Filing Documents

• crl-20250114.htm (8-K) — 39KB
• 0001100682-25-000003.txt ( ) — 163KB
• crl-20250114.xsd (EX-101.SCH) — 2KB
• crl-20250114_lab.xml (EX-101.LAB) — 21KB
• crl-20250114_pre.xml (EX-101.PRE) — 12KB
• crl-20250114_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. ("Charles River", the "Company", or the "Registrant") will be presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at approximately 5:15 p.m. Eastern time. Management of the Company intends to present an overview of the Company's strategic focus, business developments, and recent trends. Included in this presentation will be statements addressing the Company's perspective on its preliminary 2025 financial outlook and business trends. In advance of the conference presentation, the Company has posted a slide presentation on the Registrant's Investor Relations section of its website at http://ir.criver.com which includes the following statements as to (1) the Company's preliminary assessment of its 2025 financial outlook and recent trends (particularly in the areas of revenue and non-GAAP operating margin), (2) recent Discovery and Safety Assessment ("DSA") Segment trends, and (3) an update regarding the Company's contract development and manufacturing organization ("CDMO") business. Preliminary 2025 Outlook and Recent Trends Expect 2025 revenue will decline organically in a similar range as estimated in 2024 DSA client demand is expected to remain relatively consistent with trends in the second half of 2024 Constrained spending from global biopharma clients due to impact of restructuring programs and pipeline reprioritization efforts Expect stable to slight improvement in demand trends from biotech clients, similar to 2024 trends DSA pricing expected to be a headwind to revenue for 2025 Lower commercial CDM

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Date: January 14, 2025 By: /s/ Matthew L. Daniel Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR